The data showed strong activation of T-lymphocytes mediated by αCD3-αHER2 SMART-Exos in an ERBB2-positive cancer cell-dependent manner in vitro, and their cytotoxicity against HER2-expressing breast cancer was CD3+T cells-dependent. This evidence concerns the gene ERBB2 and breast carcinoma.